| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,202 |
5,828 |
$540K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,105 |
1,981 |
$125K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
752 |
725 |
$97K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
793 |
684 |
$93K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
615 |
598 |
$77K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
521 |
514 |
$70K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
350 |
335 |
$46K |
| 90461 |
|
761 |
687 |
$40K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
802 |
496 |
$29K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
207 |
203 |
$28K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
936 |
906 |
$27K |
| 83655 |
|
1,302 |
1,235 |
$20K |
| 85027 |
|
1,244 |
1,193 |
$19K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
170 |
165 |
$15K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
169 |
164 |
$15K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
71 |
71 |
$14K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
327 |
322 |
$11K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
31 |
30 |
$6K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
172 |
171 |
$6K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
132 |
130 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
40 |
36 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
47 |
47 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
276 |
257 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
60 |
56 |
$2K |
| 90480 |
|
41 |
41 |
$1K |
| 99173 |
|
19 |
17 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
15 |
15 |
$1K |
| 96127 |
|
37 |
37 |
$1K |
| 99460 |
|
15 |
14 |
$735.49 |
| 83718 |
|
29 |
25 |
$549.99 |
| 84460 |
|
29 |
25 |
$433.81 |
| 84450 |
|
29 |
25 |
$425.65 |
| 90686 |
|
824 |
450 |
$411.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
16 |
12 |
$341.12 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
19 |
16 |
$322.55 |
| 96161 |
|
15 |
14 |
$266.99 |
| 82465 |
|
13 |
13 |
$133.45 |
| 81003 |
|
12 |
12 |
$61.39 |
| 90685 |
|
17 |
17 |
$8.50 |
| 90656 |
|
17 |
17 |
$8.50 |